US · KRRO · BIOTECHNOLOGY
Korro Bio, Inc. (KRRO) intrinsic value and stock valuation
$12.18as of 2026-11-21 · Mkt cap 114.46M
Data updated · price as of 2026-11-21
- P/E
- Pro
- P/B
- Pro
- P/S
- Pro
Price history
Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.
Korro Bio, Inc. DCF and intrinsic value
InvestorsCraft values KRRO with the Chepakovich two-stage DCF model — currently rated overvalued. How the model works · Run your own DCF prefilled from KRRO’s statements →
Korro Bio, Inc. Graham Number
The Graham Number is not defined for negative earnings or book value. Guide · Calculator →
How the business is doing
Fiscal 2017–2025, USD
Is it expensive?
Each multiple against its own 15-year range, or against peers where no history is available
Peers
Same-industry companies, ranked by market cap
Peer comparison
The peer comparison table is shown only to users with a Pro subscription.
Financials
Statements by fiscal year
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $6.39M | $2.27M | $0.00 | $0.00 | $14.1M |
| Operating income | -$-87.34M | -$-91.91M | -$-84.53M | -$-59M | -$-84.03M |
| Net income | -$-117.26M | -$-83.58M | -$-81.17M | -$-58.03M | -$-84.69M |
| EPSd | -$-12.47M | -$-9.37M | -$-53.05M | -$-223.19M | -$-19.03M |
| Operating cash flow | -$-78.56M | -$-60.07M | -$-67.28M | -$-53.65M | -$-32.09M |
| Capital expenditure | -$-520K | -$-17.9M | -$-7.84M | -$-5.21M | -$-4.45M |
| Free cash flow | -$-79.08M | -$-77.98M | -$-75.12M | -$-58.86M | -$-36.54M |
| Total assets | $113.5M | $226.2M | $221.7M | $73.7M | $185.4M |
| Total debt | $43.5M | $44.8M | $33.2M | $167M | $45.6M |
| Net debt | $21.7M | -$-10.88M | -$-132.94M | $130.1M | -$-34.04M |
| Total equity | $51.4M | $160.4M | $169.9M | -$-99.03M | $130.8M |
| Cash and short-term investments | $75.2M | $126.1M | $166.2M | $55.9M | $130.7M |
Income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $6.39M | $2.27M | $0.00 | $0.00 | $14.1M |
| Cost of revenue | $4.28M | $0.00 | $0.00 | $0.00 | $3.84M |
| Gross profit | $2.11M | $2.27M | $0.00 | $0.00 | $10.2M |
| Research and development expenses | $65.6M | $63.6M | $57.3M | $42.2M | $59.3M |
| Selling, general and administrative expenses | $28.2M | $30.6M | $36.5M | $16.8M | $34.9M |
| Other expenses | -$-4.28M | $0.00 | -$-9.25M | $0.00 | $0.00 |
| Operating expenses | $89.5M | $94.2M | $84.5M | $59M | $94.3M |
| Cost and expenses | $93.7M | $94.2M | $84.5M | $59M | $98.1M |
| Interest income | $0.00 | $0.00 | $0.00 | $950K | $400K |
| Interest expense | $0.00 | $0.00 | $0.00 | $120K | $760K |
| Depreciation and amortization | $4.28M | $3.56M | $3.63M | $2.51M | $3.84M |
| Ebitda | -$-83.06M | -$-88.34M | -$-80.9M | -$-56.49M | -$-80.07M |
| Operating income | -$-87.34M | -$-91.91M | -$-84.53M | -$-59M | -$-84.03M |
| Total other income/expenses, net | -$-29.28M | $8.47M | $3.39M | $980K | -$-640K |
| Income before tax | -$-116.62M | -$-83.44M | -$-81.14M | -$-58.02M | -$-84.67M |
| Income tax expense | $640K | $140K | $30K | $10K | $10K |
| Net income | -$-117.26M | -$-83.58M | -$-81.17M | -$-58.03M | -$-84.69M |
| Weighted average shares outstanding | $9.4M | $8.92M | $1.53M | $260K | $4.45M |
| Weighted average diluted shares outstanding | $9.4M | $8.92M | $1.53M | $260K | $4.45M |
Balance sheet
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Cash and short-term investments | $75.2M | $126.1M | $166.2M | $55.9M | $130.7M |
| Net receivables | $970K | $1.7M | $0.00 | $0.00 | $140K |
| Inventory | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total current assets | $82.4M | $131.5M | $172.7M | $57.1M | $134.8M |
| Property, plant and equipment, net | $16.2M | $51.6M | $42.8M | $11.9M | $36.9M |
| Goodwill and intangible assets | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Long-term investments | $12.4M | $37M | $3.41M | $4.54M | $13.4M |
| Total non-current assets | $31.1M | $94.7M | $48.9M | $16.7M | $50.6M |
| Total assets | $113.5M | $226.2M | $221.7M | $73.7M | $185.4M |
| Accounts payable | $1.65M | $3.99M | $7.28M | $2.6M | $2.75M |
| Short-term debt | $2.67M | $1.28M | $1.99M | $2.92M | $2.58M |
| Deferred revenue | $7.83M | $3.51M | $0.00 | $0.00 | $0.00 |
| Total current liabilities | $11.9M | $15M | $19.5M | $8.7M | $11.4M |
| Long-term debt | $40.8M | $43.5M | $31.2M | $164.1M | $43M |
| Deferred revenue, non-current | $7.83M | $5.91M | $0.00 | $0.00 | $0.00 |
| Total non-current liabilities | $50.1M | $50.9M | $32.3M | $164.1M | $43.1M |
| Capital lease obligations | $43.5M | $44.8M | $33.2M | $210K | $28.9M |
| Total liabilities | $62.1M | $65.8M | $51.8M | $172.8M | $54.5M |
| Common stock | $10K | $10K | $10K | $0.00 | $40K |
| Retained earnings | -$-383.85M | -$-266.59M | -$-183M | -$-101.83M | -$-180.09M |
| Accumulated other comprehensive income (loss) | $210K | $270K | -$0.00 | -$-10K | -$-60K |
| Total equity | $51.4M | $160.4M | $169.9M | -$-99.03M | $130.8M |
| Total investments | $65.8M | $107.4M | $3.41M | $23.5M | $64.5M |
| Total debt | $43.5M | $44.8M | $33.2M | $167M | $45.6M |
| Net debt | $21.7M | -$-10.88M | -$-132.94M | $130.1M | -$-34.04M |
Cash flow statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Net income | -$-117.26M | -$-83.58M | -$-81.17M | -$-58.03M | -$-21.96M |
| Depreciation and amortization | $3.79M | $3.56M | $3.63M | $2.51M | $1.59M |
| Stock-based compensation | $7.66M | $4.46M | $2.38M | $1.14M | $810K |
| Change in working capital | -$-4.43M | $13.6M | $4.28M | -$-630K | $900K |
| Accounts receivable | $730K | -$-1.7M | $0.00 | $0.00 | $0.00 |
| Inventory | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Accounts payable | -$-2.31M | -$-1.34M | $3.1M | $1.75M | $60K |
| Net cash provided by operating activities | -$-78.56M | -$-60.07M | -$-67.28M | -$-53.65M | -$-32.09M |
| Investments in property, plant and equipment | -$-520K | -$-17.9M | -$-7.84M | -$-5.21M | -$-4.45M |
| Acquisitions, net | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Net cash used for investing activities | $44M | -$-123.35M | $11.2M | $11.1M | -$-39.5M |
| Common stock issued | $690K | $67.4M | $117.3M | $60K | $30K |
| Common stock repurchased | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Dividends paid | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Net cash used for financing activities | $690K | $69.4M | $187.8M | $20K | $115.9M |
| Net change in cash | -$-33.82M | -$-114.07M | $131.6M | -$-42.57M | $44.4M |
| Cash at end of period | $25.2M | $59.1M | $173.1M | $41.5M | $84M |
| Operating cash flow | -$-78.56M | -$-60.07M | -$-67.28M | -$-53.65M | -$-32.09M |
| Capital expenditure | -$-520K | -$-17.9M | -$-7.84M | -$-5.21M | -$-4.45M |
| Free cash flow | -$-79.08M | -$-77.98M | -$-75.12M | -$-58.86M | -$-36.54M |
Line items
Line items
Line items
About Korro Bio, Inc.
Korro Bio, Inc., a biopharmaceutical firm based in Cambridge, Massachusetts, is dedicated to exploring, advancing, and bringing to market genetic therapeutics. These treatments are formulated through RNA editing technology, aiming to address a wide array of medical conditions, encompassing both uncommon and widespread diseases.
- CEO
- Ram Aiyar
- Employees
- 49
- Beta
- 2.11
Explore
Frequently asked questions
What is the intrinsic value of Korro Bio, Inc. (KRRO)?
Korro Bio, Inc. (KRRO) is currently overvalued based on the InvestorsCraft IC model — IC value is 20–50% below the price. The exact intrinsic value is available to Pro subscribers. How the IC value is calculated.
Is KRRO undervalued?
KRRO trades at a price of $12.18 (Nov 21, 2026): overvalued — IC value is 20–50% below the price.
How is the intrinsic value calculated?
InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.
How often is this page updated?
Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.